Alliance for Pandemic Preparedness

May 18, 2021

The Effectiveness of the TWO-DOSE BNT162b2 Vaccine: Analysis of Real-World Data

Category:

Topic:

Keywords (Tags):

  • The Pfizer-BioNTech vaccine was 90% effective in preventing any SARS-CoV-2 infection when comparing incidence of infection between 7-27 days after the second dose (protection period) vs 1-7 days after the first dose (reference period). The findings are based on a cohort belonging to a large health provider in Israel (n=1.2 million), of which 74% had reached the protection period. Vaccine effectiveness when comparing an infection occurring during the protection period versus in the reference period were lower among immunosuppressed participants (71%) and those aged ≥65 years (82%), with lowest vaccine effectiveness in immunosuppressed participants aged ≥65 years (52%). The immunosuppressed category included a variety of conditions such as hematopoetic or solid organ transplant, patients under immunosuppressive therapy, asplenia, and chronic renal failure. Decreases in likelihood of hospitalization following infection during the protection period vs the reference period was less pronounced in younger age groups.

Chodick et al. (May 17, 2021). The Effectiveness of the TWO-DOSE BNT162b2 Vaccine: Analysis of Real-World Data. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab438